Open Access<p>Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model</p>
Author(s) -
Xin Wang,
Jin Deng,
Chengliang Xiong,
Haishan Chen,
Qin Zhou,
Yue Xia,
Xiaofei Shao,
Hequn Zou
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s247091
Subject(s) - hyperuricemia , rosiglitazone , medicine , endocrinology , agonist , kidney , fibrosis , peroxisome proliferator activated receptor , renal function , nephropathy , kidney disease , uric acid , receptor , pharmacology , chemistry , diabetes mellitus
Hyperuricemia is an independent risk factor for renal damage and can promote the progression of chronic kidney disease (CKD). In the present study, we employ a rat model to investigate the effects of rosiglitazone (RGTZ), a peroxisome proliferator-activated receptor-gamma agonist, on the development of hyperuricemic nephropathy (HN), and we elucidate the mechanisms involved.